Assessment of the WI ETF Wellness Program

—

Oladipo Fadiran
03/18/2022

Background

- Assessment of VBID program based on:
  - Member engagement in diabetes and general preventive care
  - Adherence to recommended care
  - Cost of care and overall risk trends
  - Diabetes disease stage progression/reversal

- Time periods:
  - Baseline year: 2019
  - Evaluation year: 2021*

*only 10 months of data available

Analysis Population Definitions

Eligible

- Relationship: Employee, Spouse
- Filled diabetes prescription with Navitus (list from Navitus)

Active (Study Group)

- Eligible Requirements **+**
  - Met requirement and enrolled in program for reduced cost diabetes drugs **for each** of 2019, 2020 and 2021*

Not Participating (Control Group)

- Eligible Requirements **+**
  - Did not enroll in reduced diabetes drugs program **in any** of years for 2019, 2020 and 2021*

*only 10 months of data available

Population Selection

Criteria	Study Group	Control Group
(Non)Participants (most recent year – 2021)	1,075	15,232
Continuously enrolled 2019 – 2021	954	12,834
At Least 1 Episode of Diabetes Each Year	545	5,252
Matched by Age, Gender and Risk Category and Diabetes Disease Stage	545	1,090

Patient Engagement Comparison

	Study Group			Control Group		
	2019	2020	2021	2019	2020	2021
Diabetes Patients	545	545	545	1,090	1,090	1,090
Preventive Adult Care Visit Per Patient*	0.47	0.41	0.45	0.45	0.39	0.40
Office Visit For Diabetes Per Patient**	3.95	3.50	3.79	3.80	3.56	3.88
Diabetes Preventive Care Visit Per Patient***	2.65	2.45	2.57	2.59	2.43	2.50

- Slightly higher utilization of preventive care among study group
  - drop for both study and control groups in 2020 due to COVID pandemic related service disruption
  - stable or marginally positive 2019 – 2021 trends in utilization for study group compared to negative trend for control group

* Includes initial or periodic comprehensive preventive medicine visits e.g. annual physical

** Office visits with a principal diagnosis of diabetes

*** Any outpatient evaluation and management primary care visit included in a diabetes episode of care

Patient Engagement Comparison – HEDIS Measures

	Study Group		Control Group	
	2019	2020	2019	2020
Diabetes Patients	545	545	1,090	1,090
HEDIS CDC Diabetes HbA1c Test Rate	93%	91%	93%	92%
HEDIS CDC Diabetes Eye Exam Rate	73%	71%	64%	63%
HEDIS SPD Statin Adherence With Diabetes Rate	85%	91%	83%	87%

- Comparable or higher adherence to expected care by the study group
  - Marked disparity of close to 10% specific to the recommended eye exams for diabetics
  - Slight drop for both groups in 2020 due to the COVID pandemic service disruption, the exception is adherence to statins and Rx benefit that was not affected by the pandemic

* Most recent HEDIS measure for 2021 are not yet available

Patient Unplanned Utilization Of Services

	Study Group			Control Group		
	2019	2020	2021	2019	2020	2021
Diabetes Patients	545	545	545	1,090	1,090	1,090
ER Visits Per 1000 (Not Resulting in Admission)	499	389	377	388	332	385
Diabetes Related Admits Per 1000	16.51	23.85	17.61	21.10	33.03	45.14
Diabetes Related ER Visits Per 1000	33.03	20.18	17.61	24.77	15.60	41.83
% of Diabetes Episodes due to Flare Ups	3.3%	3.5%	4.6%	5.3%	4.7%	5.2%

- The study group performs generally better with lower unplanned utilization of services
  - ER visits not leading to admissions started out much higher with the study group, but has decline by almost 25% from 2019 – 2012, compared to an almost flat trend for the control group for the same period
  - Diabetes related ER visits and admissions are either flat or trending lower for the study group, this is compared to marked increases for both measures for the control group from 2019 – 2021

*Note that the rates should be interpreted in the context of the relatively small populations, for example the 17.61 ER visits rate for the study group is the equivalent of 8 visits

Member Total Cost and Risk Score Transitions

	Study Group		Control Group	
	2019	2020	2019	2020
Members	545	545	1,090	1,090
NonRescaled Risk Score	541	550	536	574
Rx Cost PMPY	$8,509	$9,896	$8,301	$9,845
Medical Cost PMPY	$14,778	$14,999	$14,536	$15,385
Medical+Rx Cost PMPY	$23,287	$24,896	$22,838	$25,231

- About 10.5% increase in average Medical + Rx costs to $25,231 for the control group, compared to about 6% increase for the study group
  - The Rx cost trends for both groups is comparable at about 16.3% vs 18.6%, but the medical costs trend for the control group is much higher than for the study group (5.8% vs 1.5%)
    - There is some evidence of prescription drug stocking at the height of the COVID pandemic in 2020, this may explain the relatively large Rx cost trends
- The control group recorded a 7.1% increase in non-rescaled risk score, compared to a 1.7% increase for the study group

* No Risk scores yet for incomplete 2021

PMPY: Per Member Per Year

Diabetes Specific Cost Trends

	Study Group					Control Group				
	2019	2020	2021*	% Change 2019-2020	% Change 2020-2021	2019	2020	2021*	% Change 2019-2020	% Change 2020-2021
Diabetes Patients	545	545	545			1,090	1,090	1,090		
Rx Cost Per Patient	$6,007	$6,798	$5,791	**13%**	**-15%**	$5,700	$6,510	$5,527	**14%**	**-15%**
Med. Cost Per Patient	$2,205	$2,715	$2,561	**23%**	**-6%**	$2,733	$3,029	$3,015	**11%**	**-1%**
Med. + Rx Cost Per Patient	$8,213	$9,513	$8,353	**16%**	**-12%**	$8,434	$9,540	$8,542	**13%**	**-11%**

- Total cost of managing diabetes per patient is comparable for both groups in the 2019 base year
  - The overall costs trend from 2019 – 2020 and 2020 – 2021 are also comparable for both groups
    - Note that the data from 2021 is incomplete so the listed 2020 – 2021 trends are only useful for relative comparison – the current cost for the 2021 year is growing slower for the study group at -12% compared to the control group at -11%

Disease Stage Transition for Diabetes

Study Group

	2019	2021
Stage 1	202	127
Stage 2		69
Stage 3		6

	2019	2021
Stage 1		40
Stage 2	331	272
Stage 3		19

	2019	2021
Stage 1		1
Stage 2		9
Stage 3	12	2

	Summary Study Group
Maintain	73.6%
Improve	9.2%
Decline	17.2%

Control Group

	2019	2021
Stage 1	385	225
Stage 2		147
Stage 3		13

	2019	2021
Stage 1		95
Stage 2	672	537
Stage 3		40

	2019	2021
Stage 1		2
Stage 2		19
Stage 3	32	11

	Summary Control Group
Maintain	70.9%
Improve	10.6%
Decline	18.4%

- The combination of patients with improved or maintained disease stages is only slightly higher for the study group (82.8%)
- The biggest concern is for patients transitioning from stages 1/2 to stage 3, this was slightly higher for the control group at (4.8% vs 4.6%)

Diabetes Disease Stages – Average Costs (All WI ETF 2020 Incurred Data)

	Rx Cost/Patient	Medical Cost/Patient	Medical + Rx Cost/patient
Stage 1	$2,692	$1,188	$3,880
Stage 2	$5,298	$1,791	$7,089
Stage 3	$2,641	$18,928	$21,569
Aggregate	**$4,360**	**$2,642**	**$7,003**

- Big increases in average costs between stages, primarily:
  - Rx costs from stage 1 -> 2, higher utilization of drugs in compliance
  - Medical costs from stage 2 -> 3, medical complications
- Opportunities for intervention:
  - largest increase in transition to from stage 2 to 3, complex care coordination
  - greater utilization in stages 1 and 2, lifestyle changes, adherence to drug regimen

Cohort Matching Details
(Matching is done based on data from 2019 Base Year)

Cohort Matching – Diabetes Disease Stages





Cohort Matching – Age/Gender Groups





Cohort Matching – Risk Categories





Matching – Resulting Demographics and Risk Profiles

	Study Group	Control Group	% Difference
Members	545	1,090	
Average Age	60.6	60.5	-0.1%
% Male	51%	51%	0%
Concurrent Risk Score	541	536	-0.9%

- The groups are well matched across cohort and risk categories allowing for valid comparison

Legal Disclaimer

The information contained in this publication is provided for informational purposes only. While efforts were made to verify the completeness and accuracy of the information contained in this publication, it is provided AS IS without warranty of any kind, express or implied. In addition, this information is based on IBM's current product plans and strategy, which are subject to change by IBM without notice. IBM shall not be responsible for any damages arising out of the use of, or otherwise related to, this publication or any other materials. Nothing contained in this publication is intended to, nor shall have the effect of, creating any warranties or representations from IBM or its suppliers or licensors, or altering the terms and conditions of the applicable license agreement governing the use of IBM software.

References in this presentation to IBM products, programs, or services do not imply that they will be available in all countries in which IBM operates. Product release dates and/or capabilities referenced in this presentation may change at any time at IBM's sole discretion based on market opportunities or other factors and are not intended to be a commitment to future product or feature availability in any way. Nothing contained in these materials is intended to, nor shall have the effect of, stating or implying that any activities undertaken by you will result in any specific sales, revenue growth or other results.

Performance is based on measurements and projections using standard IBM benchmarks in a controlled environment. The actual throughput or performance that any user will experience will vary depending upon many factors, including considerations such as the amount of multiprogramming in the user's job stream, the I/O configuration, the storage configuration, and the workload processed. Therefore, no assurance can be given that an individual user will achieve results similar to those stated here.

All customer examples described are presented as illustrations of how those customers have used IBM products and the results they may have achieved. Actual environmental costs and performance characteristics may vary by customer.

IBM, the IBM logo, ibm.com, Watson, and Watson Health are trademarks of International Business Machines Corp., registered in many jurisdictions worldwide. Other product and service names might be trademarks of IBM or other companies. A current list of IBM trademarks is available on the Web at "Copyright and trademark information" at ibm.com/legal/copytrade.